期刊文献+
共找到185篇文章
< 1 2 10 >
每页显示 20 50 100
Pharmacokinetics of nifedipine sustained-release tablets in healthy Chinese volunteers 被引量:3
1
作者 武静 王本杰 +2 位作者 魏春敏 卜凡龙 郭瑞臣 《Journal of Chinese Pharmaceutical Sciences》 CAS 2007年第3期192-196,共5页
Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.... Aim To establish a LC-MS method for determining the concentration of nifedipine in human plasma and to evaluate the pharmacokinetic characteristics of nifedipine sustained-release tablets. Methods A XB-C18 (5 μm, 4.6 mm ×150 mm) column and a mobile phase of methanol: 0.01 mol·L^-1ammonium acetate (60:40, V/V) were used to separate nifedipine, the detections was accuracy under atmosperic pressure electronic spray ionization (AP-ESI) mode and ion mass spectrum (m/z) of 314.9 [M+H]^+ for nifedipine, and 320.8 [M+H]^+ for lorazepam (Internal Standard, IS). Results The linear range of nifedipine was 0.3 - 80 ng·mL^-1 ( r = 0.9997), and the limit of quantitation (LOQ) was 0.3 ng·mL^-1. The nifedipine pharmacokinetic parameters after a single dose of 20 mg nifedipine sustained-release tablets test (T) or reference (R) were as the followings, t1/2 (6.73 ± 2.00) h and (7.04 ± 2.18) h, Tmax (4.28 ± 0.70) h and (4.48 ± 0.70) h, Cmax(39.66 ± 10.58) ng·mL^-1 and (40.19 ± 10.97) ng·mL^-1, AUC0-36 (391.63 ± 108.55) ng·mL^-1·h and (387.57 ± 121.51) ng·mL^-1·h, and AUC0-∞ (408.28 ± 121.16) ng·mL^-1·h and (406.15 ± 133.13) ng·mL^-1·h. The relative bioavailability of nifedipine sustained-release tablets (test) was (103.02 ± 13.93) %. Conclusion LC-MS method for the determination of concentrations of nifedipine in human plasma was sensitive and accurate, and could be used in nifedipine bioavailability and pharmacokinetic studies. 展开更多
关键词 Nifedipine sustained-release tablets LC-MS PHARMACOKINETICS BIOEQUIVALENCE
下载PDF
Preparation and <i>in Vitro</i>Drug Release Evaluation of Once-Daily Metformin Hydrochloride Sustained-Release Tablets 被引量:1
2
作者 Ling Zhao Yumeng Wei +4 位作者 Yong Mei Li Yang Yuan You Xufeng Yang Yanhong Jiang 《Pharmacology & Pharmacy》 2012年第4期468-473,共6页
The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitr... The objective of this study was to develop once-daily metformin hydrochloride sustained-release tablets (MHSRT) and evaluate their in vitro release behavior. MHSRT were prepared by the film coating method. The in vitro drug release rate of MHSRT and the commercial tablets Fortamet? made in the United States of America in water was fitted with zero order kinetic equation, and Ritger-Peppas kinetic equation in 0.1 M HCl and pH 6.8-phosphate buffer, respectively. The similarity factor f2 values of MHSRT in three different dissolution medium were 82, 80 and 74, respectively in comparison with imported Fortamet?, which were all greater than 50. The results of storage-stability showed that MHSRT were stable for at least 6 months under stress condition (40℃ ± 2℃, RH 75% ± 5%). Therefore, in this study, MHSRT were successfully prepared using optimized formulation technologies that meet mass produce. The in vitro release behavior of MHSRT was almost similar to that of imported Fortamet?. 展开更多
关键词 sustained-release tablets METFORMIN HYDROCHLORIDE In Vitro Release Rate Similarity Factor Kinetic Model
下载PDF
Preparation and evaluation of sustained-release azithromycin tablets in vitro and in vivo
3
作者 Le Sun Weixiang Zhang +1 位作者 Xiaohong Liu Jin Sun 《Asian Journal of Pharmaceutical Sciences》 SCIE CAS 2014年第3期155-161,共7页
The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.... The objective of this study was to prepare azithromycin(AZI)sustained-release products in order to allow for a high dose to be administered,reduce gastrointestinal side-effects and increase the compliance of patients.AZI sustained-release tablets with different release performance(F-I:T_(100%)=3 h and F-II:T_(100%)=8 h in pH 6.0 phosphate buffer)were successfully prepared by wet granulation.The in vitro release rate and drug release mechanism were studied.The release rate of F-Iwas affected by dissolutionmedia with different pH,but not for F-II.HixsoneCrowellmodel was the best regression fitting model for F-I and F-II.Additionally,F-I and F-II both belonged to non-Fick diffusion.Oral pharmacokinetics of the two tablets and one AZI dispersible tablet as reference were studied in six healthy beagle dogs after oral administration.Compared with the reference,the C_(max) of F-I and F-II were decreased,and the T_(max) were prolonged,in that case which meet the requirement of sustained-release tablets.The relative bioavailability of F-I and F-II were 79.12%and 64.09%.T-test ofAUC_(0-144),and AUC_(0-∞) for F-I and F-II indicated there was no significant difference between F-I and F-II.These mean that the extended release rate did not induce different pharmacokinetics in vivo. 展开更多
关键词 AZITHROMYCIN sustained-release tablet PHARMACOKINETICS UPLC-MS-MS
下载PDF
Clinical observation of Baitou Weng Decoction combined with mesalazine sustained-release tablets in treating heat-toxic and smoldering ulcerative colitis
4
作者 Qian-Zhang Ma Yun Li Yuan-Quan Ding 《Journal of Hainan Medical University》 2019年第12期37-42,共6页
Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and ser... Objective:To observe the clinical efficacy of Baitou Weng Decoction combined with mesalazine sustained-release tablets in the treatment of ulcerative colitis with febrile heat and its effect on immune function and serum inflammatory factors.Methods: A total of 84 patients with ulcerative colitis were randomly divided into control group and treatment group, with 42 cases in each group. The control group was given mesalazine sustained-release tablets orally, while the treatment group was given Baitou Weng Decoction and mesalazine sustained-release tablets orally. The treatment period was 30 days and the patients were followed up for 3 months. After treatment, the clinical efficacy, quality of life, immune function and serum inflammatory factors of the two groups were observed.Results: The effective rate of treatment group (90.47%) was higher than that of control group (73.81%) (P<0.05);compared with before treatment, the scores of inflammatory bowel disease quality of life questionnaire scale in both groups were significantly improved (P<0.05), and the difference between the two groups was significant (P<0.05);after treatment, the plasma CD4+/CD8+ ratio and NK+ levels in both groups were significantly higher than those before treatment (P<0.05), and the treatment group was changed. The serum levels of tumor necrosis factor-α, interleukin-17 and interleukin-23 were significantly decreased in both groups after treatment (P<0.05), and the improvement was more significant in the treatment group (P<0.05). No significant adverse reactions were observed in the treatment group.Conclusions: Modified Baitou Weng Decoction combined with mesalazine in the treatment of heat-toxic and incandescent ulcerative colitis can significantly improve the clinical efficacy, improve the quality of life of patients, effectively regulate the expression level of serum inflammatory factors in ulcerative colitis patients, promote the recovery of patients' immune function, and have high drug safety. 展开更多
关键词 Baitou WENG DECOCTION MESALAZINE sustained-release tablets Hot toxicity ULCERATIVE colitis Immune function Serum inflammatory factor
下载PDF
Clinical observation on treatment of cancer pain with TCM oriented drugs combined with oxycodone sustained-release tablets and nimesulide sustained-release tablets
5
作者 Feng-Jiao He Ke-Xiong Li +2 位作者 Pu-Hua Zeng Hai-Yan Yi Xiao-Lan Jian 《TMR Cancer》 2018年第4期118-123,共6页
Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divi... Objective: To study the effect of the transdermal preparation of traditional Chinese medicine in treating cancer pain. Methods: From October 2016 to January 2018, 126 patients with cancer pain were enrolled and divided into 4 groups, 39 patients in group A (directed TCM permeation), 26 patients in group B (oxycodone sustained-release tablets), 32 patients in group C (Chinese medicine directed drug penetration + oxycodone sustained-release tablets), and 29 patients group D (Chinese medicine directed drug penetration + oxycodone sustained-release tablets + nimesulide sustained release tablets), according to KPS scores. Results: Transdermal preparations of traditional Chinese medicine can significantly alleviate cancer pain. For the treatment of moderate to severe cancer pain, the Chinese medicine transdermal preparation can reduce the dosage of oxycodone sustained-release tablets. At the same time, the patient's KPS and NRS scores were significantly reduced. Moreover, the transdermal preparation of traditional Chinese medicine has a better therapeutic effect on visceral pain. Conclusion: The traditional Chinese medicine tra_nsdermal preparation combined with western medicine for the treatment of cancer pain may be a new method for the treatment of cancer pain. 展开更多
关键词 Chinese medicine directed drug Oxycodone sustained-release tablets Cancer pain Clinical efficacy
下载PDF
Pharmacokinetic Study on Lovastatin Sustained-release Tablet and Sustained-release Capsule in Begal Dogs
6
作者 付琳 代宗顺 +1 位作者 侯淑贤 万元胜 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2004年第2期116-119,共4页
This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagl... This study pharmacokinetically examined the lovastatin sustained-release tablet and sustained-release capsule in Beagle dogs. An reversed-phase HPLC method was established for the determination of lovastatin in Beagle dog plasma. Pharmacokinetic findings were compared among three preparation(lovastatin sustained-release tablet,T p; sustained-release capsule,T J and conventional capsule). Our results showed that the pharmacokinetic parameters in 6 dogs after single-dose oral administration of three perparations were calculated. T max, C max and MRT revealed significant difference (P<0.05). Relative bioavailability was 111.5±16.9 % (T P) and 110.4%±9.6 % (T J). The pharmacokinetic parameters in the 6 dogs after multiple-dose oral administration of three perparations, T max, C max MRT and DF had significant difference (P<0.05); C av , C min and AUC 0-24 h displayed no significant difference (P>0.05). It is concluded that the lovastatin sustained-release tablet and sustained-release capsule are able to maintain a sustained-release for 24 h. 展开更多
关键词 LOVASTATIN sustained-release tablets sustained-release capsules PHARMACOKINETIC SINGLE-DOSE MULTIPLE-DOSE
下载PDF
Simultaneous Analysis of Indapamide and Related Impurities in Sustained-Release Tablets by a Single-Run HPLC-PDA Method
7
作者 YAO Wu ZHOU Shiwen CHENG Qiongru 《Wuhan University Journal of Natural Sciences》 CAS CSCD 2023年第4期333-340,共8页
The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array dete... The contents of indapamide and related impurities in generic indapamide sustained-release tablets were simultaneously detected by a single-run high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)method for the quality control in this paper.The results showed the method had a good selectivity and was validated through linearity,limits of detection and quantification,recovery,and precision.The linear ranges of indapamide,2-methyl-1-nitroso-2,3-dihydro-1H-indole(impurity A,ImA),4-chloro-N-(2-methyl-1H-indol-1-yl)-3-sulphamoyl-benzamide(impurity B,ImB)and 4-chloro-3-sulfamoylbenzoic acid(impurity 1,Im1)were 0.028-1.80μg/mL(R=0.99995),0.060-1.20μg/mL(R=0.9996),0.0324-1.20μg/mL(R=0.99985)and 0.060-1.20μg/mL(R=0.9997)with detection limits of 0.0093,0.012,0.012 and 0.006μg/mL,respectively.ImA and Im1 were not detectable in the generic drug.The content of indapamide was 96.7%of the labeled amount with a relative standard deviation(RSD)of 1.30%,and the percentage of ImB relative to the labeled amounts of indapamide was 0.106%with an RSD of 1.82%.The content of other unspecified impurities all met the reference quality standards.The results provided references for the quality control and the quality standard study of generic indapamide sustained-release tablets. 展开更多
关键词 INDAPAMIDE related impurity sustained-release tablets high performance liquid chromatography equipped with photodiode array detector(HPLC-PDA)
原文传递
犀角地黄汤联合来氟米特对系统性红斑狼疮的改善作用 被引量:2
8
作者 王伟 付军燕 +2 位作者 郭凤霞 谷洪 孙金磊 《西北药学杂志》 2024年第1期162-166,共5页
目的观察犀角地黄汤联合来氟米特对系统性红斑狼疮(systemic lupus erythema,SLE)的改善及对Th1/Th2失衡的影响。方法选取123例急性活动期热毒炽盛证SLE患者,用随机数字表法分为对照组(n=61)和试验组(n=62)。对照组采用醋酸泼尼松片联... 目的观察犀角地黄汤联合来氟米特对系统性红斑狼疮(systemic lupus erythema,SLE)的改善及对Th1/Th2失衡的影响。方法选取123例急性活动期热毒炽盛证SLE患者,用随机数字表法分为对照组(n=61)和试验组(n=62)。对照组采用醋酸泼尼松片联合来氟米特治疗,试验组在对照组治疗的基础上用犀角地黄汤治疗。比较治疗前、治疗后1个月和治疗后3个月2组疾病活动度评分、中医证候评分、补体C3水平和Th1/Th2值;比较2组抗ds-DNA抗体阳性率、临床疗效和不良反应。结果治疗前2组SLE疾病活动度评分(SLE disease activity score,SLEDAI)、中医证候评分、补体C3水平和Th1/Th2值比较,差异无统计学意义;治疗后1、3个月试验组SLEDAI评分、中医证候评分、Th1/Th2值和抗ds-DNA抗体阳性率均明显低于对照组,补体C3水平和临床总有效率均明显高于对照组(P<0.05);试验组不良反应发生率明显低于对照组(P<0.05)。结论犀角地黄汤可改善急性活动期热毒炽盛证SLE患者疾病活动度及中医证候、实验室指标,提升临床疗效,减少糖皮质激素及免疫抑制剂所致的不良反应。 展开更多
关键词 犀角地黄汤 来氟米特 醋酸泼尼松片 系统性红斑狼疮 急性活动期 热毒炽盛证
下载PDF
Qualitative and quantitative analysis of HPLC fingerprint of Wuji gastric floating sustained-release tablets 被引量:1
9
作者 陈中芬 刘文 +2 位作者 陈大业 施晓伟 王群 《Journal of Chinese Pharmaceutical Sciences》 CAS CSCD 2015年第5期310-317,共8页
A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 co... A qualitative and quantitative test method of fingerprint of Wuji gastric floating sustained-release tablets was established. High performance liquid chromatography (HPLC) was adopted, using Agilent ZORBAX SB-C18 column (250 mm×4.6 mm, 5 μm) as the chromatographic column, and acetonitrile-0.05 mol/L potassium dihydrogen phosphate solution as the mobile phase in a gradient elution with the flow rate of 1.0 mL/min. Sample solution (10 μL) was injected and was tested at the wavelength of 225 nm for 75 min at the column temperature of 30 ℃, Fingerprint similarity software (2004A version) was used to conduct data analysis. A total of 11 batches of Wuji gastric floating sustained-release tablets were tested and analyzed with HPLC fingerprint. Seventeen common peaks were found and the similarity of the 11 batches of agents was greater than 0.9, indicating that the production process of the agent is stable and feasible. The method is operable and could effectively control the quality of Wuji gastric floating sustained-release tablets. 展开更多
关键词 FINGERPRINT HPLC Wuji gastric floating sustained-release tablets
原文传递
强的松片联合白芍总苷胶囊治疗激素依赖性亚急性甲状腺炎阴虚火旺证的临床研究
10
作者 朱平 陆羽 +4 位作者 王凯 刘新亮 黄玉杰 颜婷 李鞠 《中国医药导报》 CAS 2024年第15期56-59,共4页
目的 探讨强的松片联合白芍总苷胶囊治疗激素依赖性亚急性甲状腺炎(SDSAT)阴虚火旺证的效果。方法 选取2019年10月至2023年7月江苏省淮安市肿瘤医院收治的62例SDSAT阴虚火旺证患者,采用随机数字表法将其分成激素组与联合组,各31例。激... 目的 探讨强的松片联合白芍总苷胶囊治疗激素依赖性亚急性甲状腺炎(SDSAT)阴虚火旺证的效果。方法 选取2019年10月至2023年7月江苏省淮安市肿瘤医院收治的62例SDSAT阴虚火旺证患者,采用随机数字表法将其分成激素组与联合组,各31例。激素组采用强的松片治疗每周减量5 mg,连续治疗直至停药,联合组在此基础上给予白芍总苷胶囊治疗,连续治疗8周。观察两组治疗前后中医证候积分、红细胞沉降率(ESR)与甲状腺功能指标、炎症指标、临床疗效及不良反应总发生率。结果 治疗后,两组中医证候积分低于治疗前,且联合组低于激素组(P<0.05)。治疗后,两组ESR、游离三碘甲状腺原氨酸、游离甲状腺素水平低于治疗前,且联合组低于激素组;两组促甲状腺激素水平高于治疗前,且联合组高于激素组(P<0.05)。治疗后,两组转化生长因子-β1水平高于治疗前,且联合组高于激素组;两组白细胞介素-17水平低于治疗前,且联合组低于激素组(P<0.05)。联合组临床疗效优于激素组(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 强的松片联合白芍总苷胶囊能够改善患者炎症水平及实验室指标,降低中医证候积分,提高临床疗效,减少复发,且不良反应少,安全性较高。 展开更多
关键词 激素依赖性亚急性甲状腺炎 强的松片 白芍总苷胶囊 临床疗效 不良反应
下载PDF
润肺固肾汤联合吡非尼酮片、醋酸泼尼松片治疗进展性肺纤维化(肺肾气阴两虚证)的疗效观察
11
作者 焦晨雪 刘建伟 +2 位作者 张云云 曹洁 徐娜 《中国医院用药评价与分析》 2024年第6期693-696,共4页
目的:探讨润肺固肾汤联合吡非尼酮片、醋酸泼尼松片治疗进展性肺纤维化(肺肾气阴两虚证)的疗效。方法:选取2021年2月至2023年6月该院收治的进展性肺纤维化(肺肾气阴两虚证)患者120例,采用随机数字表法分为观察组(n=60)和对照组(n=60)。... 目的:探讨润肺固肾汤联合吡非尼酮片、醋酸泼尼松片治疗进展性肺纤维化(肺肾气阴两虚证)的疗效。方法:选取2021年2月至2023年6月该院收治的进展性肺纤维化(肺肾气阴两虚证)患者120例,采用随机数字表法分为观察组(n=60)和对照组(n=60)。对照组患者实施吡非尼酮片+醋酸泼尼松片治疗,观察组患者在对照组的基础上联合润肺固肾汤治疗,均持续治疗12周。比较两组患者治疗前后高分辨率CT(HRCT)影像学评分、运动耐力[6 min步行试验距离(6MWD)]、生活质量[圣乔治呼吸问卷(SGRQ)评分]、肺功能[第1秒用力呼气容积(FEV_(1))、用力肺活量(FVC)及最大呼气流量(MEF)]和纤维化指标[血清涎液化糖链抗原-6(KL-6)]水平;评估临床疗效、用药安全性。结果:观察组患者的总有效率为95.00%(57/60),较对照组的81.67%(49/60)更高,差异有统计学意义(P<0.05)。治疗后,两组患者HRCT影像学评分、SGRQ评分和血清KL-6水平较治疗前显著降低,6MWD、FEV_(1)、FVC和MEF水平较治疗前显著升高;观察组患者HRCT影像学评分、SGRQ评分和血清KL-6水平较对照组更低,6MWD、FEV_(1)、FVC和MEF水平较对照组更高,差异均有统计学意义(P<0.05)。对照组、观察组患者的不良反应总发生率分别为8.33%(5/60)、10.00%(6/60),差异无统计学意义(P>0.05)。结论:润肺固肾汤联合吡非尼酮片、醋酸泼尼松片可有效缓解进展性肺纤维化(肺肾气阴两虚证)患者的临床症状和肺纤维化程度,改善运动耐力和生活质量,提高肺功能及临床疗效,安全性好。 展开更多
关键词 润肺固肾汤 吡非尼酮片 醋酸泼尼松片 肺肾气阴两虚证 进展性肺纤维化 疗效
下载PDF
纤溶酶注射液联合醋酸泼尼松片对突发性耳聋患者血液流变学及炎性因子水平的影响
12
作者 王春龙 《药品评价》 CAS 2024年第5期613-616,共4页
目的研究纤溶酶注射液联合醋酸泼尼松片治疗突发性耳聋对患者血液流变学及炎性因子水平的影响。方法以配对原则收集2021年11月至2023年11月南阳市第一人民医院104例突发性耳聋患者,按不同治疗方案分为对照组(醋酸泼尼松片治疗)、联合组... 目的研究纤溶酶注射液联合醋酸泼尼松片治疗突发性耳聋对患者血液流变学及炎性因子水平的影响。方法以配对原则收集2021年11月至2023年11月南阳市第一人民医院104例突发性耳聋患者,按不同治疗方案分为对照组(醋酸泼尼松片治疗)、联合组(纤溶酶注射液+醋酸泼尼松片治疗),各52例。治疗10 d后,比较两组疗效,不良反应发生率,不同频率听阈值,血液流变学[全血低切黏度(LBV)、全血高切黏度(HBV)、血细胞比容(HCT)、血浆黏度(PV)],炎性因子[白细胞介素-1β(IL-1β)、IL-6]及凋亡蛋白[半胱氨酸天冬氨酸蛋白酶3(Caspase-3)、p53蛋白]水平。结果联合组总有效率较对照组高(94.23%>80.77%)(P<0.05);治疗后联合组0.5 kHz、1 kHz、2 kHz听阈值低于对照组(P<0.05);治疗后联合组LBV、HBV、HCT、PV、IL-1β、IL-6、Caspase-3、p53蛋白低于对照组(P<0.05);两组不良反应发生率(7.69%vs 11.54%)相比,差异无统计学意义(P>0.05)。结论纤溶酶注射液联合醋酸泼尼松片治疗突发性耳聋安全有效,可抑制炎性反应及听毛细胞凋亡,改善血液流变学,有效降低纯音听阈值。 展开更多
关键词 纤溶酶注射液 醋酸泼尼松片 突发性耳聋 疗效 听阈值
下载PDF
慢性阻塞性肺气肿的临床症状及治疗效果分析
13
作者 赵金牛 崔连明 孙长亮 《中国实用医药》 2024年第10期106-108,共3页
目的 探讨慢性阻塞性肺气肿的临床症状及治疗效果。方法 选取100例慢性阻塞性肺气肿患者为研究对象,按照随机数字表原则将患者分为对照组及观察组,每组50例。对照组应用常规治疗,观察组在对照组的基础上联用泼尼松片治疗。比较两组患者... 目的 探讨慢性阻塞性肺气肿的临床症状及治疗效果。方法 选取100例慢性阻塞性肺气肿患者为研究对象,按照随机数字表原则将患者分为对照组及观察组,每组50例。对照组应用常规治疗,观察组在对照组的基础上联用泼尼松片治疗。比较两组患者的临床症状评分,临床治疗效果,用药不良反应发生情况。结果 用药7 d后,观察组患者的胸闷、呼吸困难、咳痰、嗜睡评分分别为(0.85±0.21)、(0.90±0.24)、(0.81±0.20)、(0.88±0.26)分,低于对照组的(1.27±0.28)、(1.34±0.35)、(1.23±0.25)、(1.20±0.31)分,比较有差异(P<0.05)。观察组临床治疗总有效率98.00%大于对照组的80.00%,比较有差异(P<0.05)。两组患者的用药不良反应发生率比较无差异(P>0.05)。结论 慢性阻塞性肺气肿发生后,常规治疗的同时联合应用泼尼松片治疗,可有效改善临床症状,提高治疗效果,还可保障治疗安全性。 展开更多
关键词 慢性阻塞性肺气肿 临床症状评分 泼尼松片 治疗效果 用药不良反应
下载PDF
小剂量泼尼松片单用及联合顽痹康丸对风湿性多肌痛患者疼痛症状及血清炎症因子水平的影响比较
14
作者 张丽丽 李登宇 +4 位作者 王笑青 张万义 柳维 沙莎 赵冬梅 《齐齐哈尔医学院学报》 2024年第21期2044-2048,共5页
目的探究小剂量泼尼松片单用及联合顽痹康丸对风湿性多肌痛患者疼痛症状及血清炎症因子水平的影响,为中药制剂治疗风湿性多肌痛提供理论依据。方法选择2020年7月-2023年12月本院收治的67例风湿性多肌痛患者为研究对象,随机数表法分为对... 目的探究小剂量泼尼松片单用及联合顽痹康丸对风湿性多肌痛患者疼痛症状及血清炎症因子水平的影响,为中药制剂治疗风湿性多肌痛提供理论依据。方法选择2020年7月-2023年12月本院收治的67例风湿性多肌痛患者为研究对象,随机数表法分为对照组(小剂量泼尼松片单用)及观察组(小剂量泼尼松片联合顽痹康丸治疗)两组,观察组3例、对照组2例未能坚持完成治疗,予以剔除。最终观察组30例,对照组32例。比较两组疗效,治疗前、治疗后视觉模拟疼痛评分(VAS)、上肢失举度、激素用量、血常规、尿常规、肝肾功能及血沉(ESR)、C-反应蛋白(CRP)、白介素-6(IL-6)变化,对比两组不良反应及复发率。结果治疗前、治疗4周后、治疗8周后、治疗12周后对照组、观察组VAS评分、上肢失举度、ESR、CRP、IL-6比较存在明显的交互、组间和时间差异(P<0.05);治疗4周后、治疗8周后、治疗12周后观察组均低于对照组(P<0.05)。治疗8周后、12周后观察组激素用量较对照组明显低(P<0.05)。治疗前、治疗4周后两组血小板计数、血红蛋白、谷丙转氨酶、血肌酐、尿素氮比较,差异无统计学意义(P>0.05)。治疗后观察组不良反应总发生率、治疗后半年复发略低于对照组(P>0.05)。结论小剂量泼泥松片联合顽痹康丸治疗风湿性多肌痛可提高患者治疗效果,有效缓解患者疼痛症状、抑制机体炎症反应,减少治疗后患者激素用量,安全性高。 展开更多
关键词 风湿性多肌痛 泼尼松片 顽痹康丸 疼痛症状 炎症因子
下载PDF
双嘧达莫联合醋酸泼尼松片治疗肾病综合征患儿的效果观察 被引量:1
15
作者 韩虹 张靖 +2 位作者 朱彩华 孙文武 马远 《中国合理用药探索》 CAS 2023年第9期19-23,共5页
目的:探讨双嘧达莫联合醋酸泼尼松片治疗肾病综合征(NS)患儿的临床效果。方法:选取2019年10月~2021年10月期间某院收治的102例NS患儿作为研究对象,根据双盲法分为对照组与观察组,每组51例。两组均给予常规治疗,对照组在常规治疗基础上... 目的:探讨双嘧达莫联合醋酸泼尼松片治疗肾病综合征(NS)患儿的临床效果。方法:选取2019年10月~2021年10月期间某院收治的102例NS患儿作为研究对象,根据双盲法分为对照组与观察组,每组51例。两组均给予常规治疗,对照组在常规治疗基础上加用醋酸泼尼松片,观察组在对照组基础上加用双嘧达莫片。比较两组患者临床症状情况、肾功能指标[血清肌酐(Scr)、血尿素氮(BUN)、24h尿蛋白]、凝血功能指标[活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)]及治疗期间不良反应的发生情况。结果:治疗后,观察组尿量增加时间、水肿消退时间均短于对照组(P<0.05);两组Scr、BUN、24h尿蛋白水平均低于治疗前(P<0.05),且观察组低于对照组(P<0.05);两组APTT、PT均高于治疗前(P<0.05),且观察组高于对照组(P<0.05);治疗期间,两组患儿皮疹、恶心、呕吐及食欲不振等不良反应的总发生率比较无统计学差异(P>0.05)。结论:双嘧达莫联合醋酸泼尼松片治疗可有效缓解NS患儿的临床症状,改善其肾功能及凝血功能,且未增加不良反应。 展开更多
关键词 肾病综合征 醋酸泼尼松片 双嘧达莫 肾功能 凝血指标
下载PDF
补肾活血方对慢性免疫性血小板减少症模型小鼠VEC相关血管因子的影响 被引量:1
16
作者 刘晓 费飞 秦兰 《辽宁中医杂志》 CAS 2023年第2期191-195,F0003,共6页
目的 探讨补肾活血方对慢性免疫性血小板减少症(chronic immune thrombocytopenia, CITP)的治疗作用及效应机制。方法 80只小鼠随机分为4组(对照组、ITP模型组、醋酸泼尼松组和补肾活血方组),采用被动免疫造模法建立CITP小鼠模型,第8天... 目的 探讨补肾活血方对慢性免疫性血小板减少症(chronic immune thrombocytopenia, CITP)的治疗作用及效应机制。方法 80只小鼠随机分为4组(对照组、ITP模型组、醋酸泼尼松组和补肾活血方组),采用被动免疫造模法建立CITP小鼠模型,第8天进行模型评估后,以补肾活血方、醋酸泼尼松进行药物干预14 d,采用酶联免疫吸附测定法(enzyme-linked immuno sorbent assay, ELISA)检测小鼠血管内皮细胞相关血管因子含量的影响。结果 与模型组比较,补肾活血方组、醋酸泼尼松组治疗14 d后,能显著提升血小板数目,显著降低前列环素(epoprostenol, PGI2)水平(P<0.05);而血浆血栓素(thromboxane, TXA2)、血小板激活因子(platelet activating factor, PAF)、血管内皮生长因子(vascular endothelial growth factor, VEGF)含量显著升高。补肾活血方组对TXA2、VEGF含量升高效果显著优于醋酸泼尼松组。结论 补肾活血方能够影响慢性免疫性血小板减少症模型小鼠血管内皮细胞相关血管因子TXA2、PGI2、PAF以及VEGR的水平,从而影响外周血小板数目,促进血管内皮细胞(vascular endothelial cell, VEC)修复,加强止血效应。而且,VEGF可作为评价ITP治疗及预后的指标。 展开更多
关键词 补肾活血方 醋酸泼尼松片 慢性免疫性血小板减少症 血管内皮细胞 血管内皮生长因子 血浆血栓素 血小板激活因子 前列环素
下载PDF
白芍总苷胶囊联合泼尼松片对儿童系统性红斑狼疮的疗效观察 被引量:2
17
作者 张俊霞 时利玲 +1 位作者 柴焕然 张敬芳 《临床研究》 2023年第1期107-110,共4页
目的探讨儿童系统性红斑狼疮(SLE)采用白芍总苷胶囊联合泼尼松片治疗的疗效。方法选取2019年1月至2022年7月濮阳市人民医院儿科收治的共计82例SLE患儿,按照随机数字表法分成治疗组(N=41)与对照组(N=41),对照组采用泼尼松片治疗,治疗组... 目的探讨儿童系统性红斑狼疮(SLE)采用白芍总苷胶囊联合泼尼松片治疗的疗效。方法选取2019年1月至2022年7月濮阳市人民医院儿科收治的共计82例SLE患儿,按照随机数字表法分成治疗组(N=41)与对照组(N=41),对照组采用泼尼松片治疗,治疗组采用白芍总苷胶囊联合泼尼松片治疗。对两组临床疗效、免疫功能、肝肾功能及不良反应发生情况进行比较。结果治疗组治疗有效率(95.12%)较对照组(80.49%)更高,差异有统计学意义(P<0.05);治疗后两组补体3(C3)、补体4(C4)水平较治疗前提高,差异有统计学意义(P<0.05);免疫球蛋白A(IgA)、免疫球蛋白G(IgG)、免疫球蛋白M(IgM)水平较治疗前降低,差异有统计学意义(P<0.05),与对照组比较,治疗组C3水平更高,差异有统计学意义(P<0.05),IgA、IgG、IgM水平更低,差异有统计学意义(P<0.05);治疗后两组谷草转氨酶(AST)、谷丙转氨酶(ALT)、血肌酐(Cr)及血尿素氮(BUN)水平降低,差异有统计学意义(P<0.05),治疗组水平较对照组更低,差异有统计学意义(P<0.05);治疗组不良反应发生率(4.88%)较对照组(21.95%)更低,差异有统计学意义(P<0.05)。结论白芍总苷胶囊联合泼尼松片用于治疗儿童SLE,能够提高临床疗效,增强机体免疫功能,促进患儿肝肾功能恢复,降低不良反应发生率。 展开更多
关键词 系统性红斑狼疮儿童 白芍总苷胶囊 泼尼松片 疗效 免疫功能
下载PDF
尼达尼布联合醋酸泼尼松片治疗间质性肺炎的临床效果及安全性分析 被引量:1
18
作者 赵亚男 张莉 +2 位作者 宋静 巫雪飞 李长生 《中国医学创新》 CAS 2023年第5期14-18,共5页
目的:探讨尼达尼布联合醋酸泼尼松片治疗间质性肺炎的临床效果及安全性,进而评估其临床应用价值。方法:选取清华大学附属北京清华长庚医院2019年2月-2021年1月收治的间质性肺炎患者共160例,采用随机数字表法分为比较组和试验组,各80例... 目的:探讨尼达尼布联合醋酸泼尼松片治疗间质性肺炎的临床效果及安全性,进而评估其临床应用价值。方法:选取清华大学附属北京清华长庚医院2019年2月-2021年1月收治的间质性肺炎患者共160例,采用随机数字表法分为比较组和试验组,各80例。比较组采用醋酸泼尼松片治疗,试验组采用醋酸泼尼松联合尼达尼布治疗。比较两组在临床症状改善情况、血清炎症因子变化、肺功能指标变化、治疗效果、不良反应发生率等方面的差异。结果:试验组发热、咳嗽、气促、肺部湿啰音消失时间均短于比较组(P<0.05)。治疗前,两组降钙素原(procalcitonin,PCT)、肿瘤坏死因子-α(tumor necrosis factor-α,TNF-α)、免疫球蛋白E(immunoglobulin E,IgE)水平比较,差异均无统计学意义(P>0.05);治疗后,两组PCT、TNF-α、IgE均有所下降,且试验组各指标均低于比较组(P<0.05)。治疗前,两组第1秒用力呼气容积(forced expiratory volume in 1 second,FEV_(1))、用力肺活量(forced vital capacity,FVC)、最大呼气流量(peak expiratory flow,PEF)水平比较,差异均无统计学意义(P>0.05);治疗后,两组FEV_(1)、FVC、PEF均有上升,且试验组各指标均高于比较组(P<0.05)。试验组治疗总有效率高于比较组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:尼达尼布联合醋酸泼尼松片治疗间质性肺炎的临床效果确切,有助于抑制机体炎症反应,改善肺功能,缓解临床症状,进而改善疾病预后。 展开更多
关键词 尼达尼布 醋酸泼尼松片 间质性肺炎 肺功能
下载PDF
早期胸腔积液引流联合醋酸泼尼松片治疗结核性渗出性胸膜炎患者的效果评价 被引量:2
19
作者 张小其 周金坊 《中国实用医药》 2023年第8期111-113,共3页
目的探讨早期胸腔积液引流联合醋酸泼尼松治疗结核性渗出性胸膜炎的疗效。方法140例结核性渗出性胸膜炎患者,依据治疗方法的不同分为对照组和观察组,每组70例。对照组采取常规抗结核药物治疗,观察组在对照组基础上实施早期胸腔积液引流... 目的探讨早期胸腔积液引流联合醋酸泼尼松治疗结核性渗出性胸膜炎的疗效。方法140例结核性渗出性胸膜炎患者,依据治疗方法的不同分为对照组和观察组,每组70例。对照组采取常规抗结核药物治疗,观察组在对照组基础上实施早期胸腔积液引流联合醋酸泼尼松片治疗。对比两组患者临床治疗效果及症状改善时间。结果观察组患者治疗总有效率94.29%高于对照组的77.14%,差异有统计学意义(P<0.05)。观察组胸腔积液吸收时间(15.36±2.13)d、结核中毒症状消失时间(9.53±2.41)d和体温恢复时间(3.68±1.12)d均短于对照组的(18.79±2.51)、(15.29±3.25)、(5.36±1.25)d,差异具有统计学意义(P<0.05)。结论在口服抗结核药物基础上进行早期胸腔积液引流联合醋酸泼尼松片治疗结核性渗出性胸膜患者,可以减少胸膜肥厚或粘连发生,值得临床推广应用。 展开更多
关键词 结核性渗出性胸膜炎 胸腔积液引流 醋酸泼尼松片 抗结核 治疗效果
下载PDF
补肺汤治疗特发性肺间质纤维化伴慢性呼吸衰竭疗效观察 被引量:3
20
作者 吴启相 刘志勇 +3 位作者 成菲 杨增祥 韩圣宾 郭丽纳 《辽宁中医杂志》 CAS 2023年第4期94-97,共4页
目的 探讨补肺汤对特发性肺间质纤维化伴慢性呼吸衰竭患者的治疗效果。方法 前瞻性选取50例2019年6月—2021年3月开封市中医院肺病科收治的特发性肺间质纤维化并发慢性呼吸衰竭患者,以随机数字表法分为对照组和试验组,各25例。对照组口... 目的 探讨补肺汤对特发性肺间质纤维化伴慢性呼吸衰竭患者的治疗效果。方法 前瞻性选取50例2019年6月—2021年3月开封市中医院肺病科收治的特发性肺间质纤维化并发慢性呼吸衰竭患者,以随机数字表法分为对照组和试验组,各25例。对照组口服乙酰半胱氨酸泡腾片、醋酸泼尼松片,试验组在对照组的基础上加用补肺汤,两组均持续治疗2周。比较两组治疗2周后的临床疗效,治疗前、治疗2周后的中医证候评分、肺功能及血气指标。结果 治疗2周后,试验组总有效率为92.00%(23/25),高于对照组的68.00%(17/25)(P<0.05)。治疗2周后,两组动则喘咳、气不接续、疲倦乏力、痰黏不易咳出、胸闷如窒评分、中医证候总分及酸碱度(pH)均低于治疗前,试验组低于对照组(P<0.05);而两组第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、一氧化碳弥散量(DLCO)及二氧化碳分压(PaCO_(2))、氧分压(PaO_(2))均高于治疗前,试验组高于对照组(P<0.05)。结论 补肺汤可改善特发性肺间质纤维化伴慢性呼吸衰竭患者肺功能及血气,并可改善患者中医证候,进而有利于提高临床疗效。 展开更多
关键词 特发性肺间质纤维化 慢性呼吸衰竭 补肺汤 乙酰半胱氨酸泡腾片 醋酸泼尼松片 中医证候 血气 肺功能
下载PDF
上一页 1 2 10 下一页 到第
使用帮助 返回顶部